Menu Search
Equities

Cosmo Pharmaceuticals NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert
C43:BRN

Cosmo Pharmaceuticals NV

Actions
  • Price (CHF)117.48
  • Today's Change0.00 / 0.00%
  • Shares traded3.00
  • 1 Year change--
  • Beta1.5582
Data delayed at least 15 minutes, as of Jan 27 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.

  • Revenue in CHF (TTM)166.31m
  • Net income in CHF50.40m
  • Incorporated--
  • Employees332.00
  • Location
    Cosmo Pharmaceuticals NVRiverside IISir John Rogerson's Quay, Dublin 2DUBLIN IrelandIRL
  • Phone+353 18170370
  • Websitehttps://www.cosmopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.